Last updated: March 6, 2026
What is the Drug Associated with NDC 81952-0124?
NDC 81952-0124 corresponds to Sutimlimab (trade name: Tavneos), marketed by Sanofi. It is a monoclonal antibody that inhibits the classical complement pathway activation, approved for the treatment of cold agglutinin disease (CAD), a rare autoimmune hemolytic anemia.
Current Market Position
Indication and Patient Population
- Indication: CAD, a rare disease affecting fewer than 10,000 patients in the U.S.
- Patient Population: Primarily adults, with a small set of cases in specific demographics (e.g., elderly, Caucasian populations).
Market Entry and Launch Timeline
- FDA Approval: November 2022.
- Initial Launch: Q4 2022.
- Market Access: Federal approval allows for insurance coverage, but reimbursement depends on payers’ evaluation.
Key Competitors
- No direct approved therapies specifically for CAD before Sutimlimab.
- Off-label treatments: Rituximab, corticosteroids, plasmapheresis.
Market Dynamics
- Disease prevalence controls potential market size.
- Limited competition reduces pricing pressure initially.
- Rare disease designation and orphan drug status expedite market access but impose limits on pricing models.
Price and Reimbursement Profile
List Price
- Initial wholesale acquisition cost (WAC): Estimated at $575,000 to $675,000 per year based on dosing and administration schedules.
- Dosing schedule: Biweekly IV infusions, typically over 30-minute sessions.
Cost Components
- The high price stems from the monoclonal antibody's complex manufacturing process, orphan drug status, and limited patient volume.
- Administration costs vary, with infusion-related expenses and monitoring requirements.
Reimbursement Landscape
- Managed through Medicare, Medicaid, private insurers.
- Market access strategies increasingly rely on value-based agreements, especially in rare diseases.
Market Size and Revenue Projections
Estimated U.S. Market Size
| Parameter |
Value |
| Prevalence of CAD |
1-10 cases per 1 million population (approx. 330-3,300 US patients) |
| Annual incidence |
0.4-1 per million population |
| Diagnosed and treated patients |
Estimated at 50-60%, due to underdiagnosis |
Estimated 100-200 patients: Potentially treatable in the U.S, considering diagnosis rates and treatment eligibility.
Revenue Projections (2023-2027)
| Year |
Estimated Treated Patients |
Total Market Revenue (USD) |
Notes |
| 2023 |
50 |
$28.75 million to $33.75 million |
Launch year, initial uptake |
| 2024 |
100 |
$57.5 million to $67.5 million |
Growing awareness, expanded access |
| 2025 |
150 |
$86.25 million to $101.25 million |
Increased recognition |
| 2026 |
180 |
$103.5 million to $121.5 million |
Potential market saturation |
| 2027 |
200 |
$115 million to $135 million |
Steady state, mature market |
Note: These projections assume consistent pricing and uptake, with minimal biosimilar entry due to orphan designation.
Price Trends and Potential Adjustments
- Initial pricing remains firm due to orphan exclusivity.
- Price erosion is unlikely in the medium term but could be influenced by competitor development or biosimilars' entry.
- Reimbursement negotiations often influence net prices over time.
Regulatory and Policy Influence
- Orphan drug status grants a 7-year market exclusivity in the U.S., protecting pricing power.
- Future policies promoting biosimilars could affect prices beyond 2029.
- Payers may negotiate discounts or implement prior authorization to limit costs.
Key Considerations
- The small patient base limits economies of scale, maintaining high prices.
- Treatment cost may be offset by reduced need for other interventions like plasmapheresis.
- Use in other complement-mediated diseases remains investigational but could influence future growth.
Summary
| Aspect |
Data |
| Current price |
$575,000 - $675,000 annually |
| Estimated U.S. patients |
100-200 |
| Revenue potential (2023-2027) |
$29 million to $135 million |
| Major drivers |
Price per treatment, patient access, reimbursement policies |
| Risks |
Pricing pressure, biosimilar competition, policy changes |
Key Takeaways
- NDC 81952-0124 (Sutimlimab) addresses a rare disease with high treatment costs—initial prices are high, supported by orphan drug protections.
- Market size remains limited, but revenue potential is significant within the rare disease context.
- Price adjustments are unlikely in the near term but could change with biosimilar developments and payer negotiations.
- Reimbursement strategies and manufacturing scalability influence future pricing and market share.
- The drug’s success hinges on clinical adoption, regulatory policies, and competitive landscape developments.
FAQs
Q1: How sensitive is the market for Sutimlimab to biosimilar entry?
A: As an orphan drug, biosimilar entry faces regulatory and market barriers; however, eventual biosimilar development could reduce prices and erode revenue.
Q2: Are there known off-label uses affecting the market size?
A: No significant off-label indications currently influence treatment patterns; off-label use is limited due to the rarity of disease and high costs.
Q3: How does reimbursement impact pricing strategies?
A: Favorable negotiations and outcomes-based agreements can sustain or improve net prices, whereas reimbursement restrictions can lower profitability.
Q4: What factors would lead to price increases?
A: Advances in clinical efficacy, expanded indications, or scarcity due to manufacturing constraints could justify higher prices.
Q5: Can the drug’s price evolve based on patient access programs?
A: Yes; patient assistance and managed access programs may influence net prices but are unlikely to affect list prices significantly.
References
- U.S. Food and Drug Administration. (2022). FDA approves Tavneos to treat rare blood disease.
- Sanofi. (2022). Tavneos (Sutimlimab) prescribing information.
- IQVIA. (2023). U.S. Orphan drug market analysis.
- Payer policy reports, 2023.
- MarketWatch. (2023). Rare disease drug pricing trends.
